Remove Hospitals Remove Immunization Remove Mayo Clinic
article thumbnail

Avatrombopag Receives FDA Approval for Treamtent of Pediatric Patients With Chronic Immune Thrompcytopenia

Pharmacy Times

Avatrombopag (Doptelet; Sobi) has been approved by the FDA for the treatment of pediatric patients aged 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a prior therapy. The decision is based on clinically meaningful data from the AVA-PED-301 study (NCT04516967).

article thumbnail

TikTok Videos on IBD Provide Low Quality Information

Drug Topics

2 Pharmacists can play a large role in the management of IBD, especially because medication nonadherence is common, leading to increased flares, hospitalizations, and complications. Additionally, pharmacists can make sure that patients have updated immunizations, especially for patients who are on immunosuppressive therapy.

FDA 282
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Efficiency, Education, and Evolution: What’s Next for Pharmacy Practice?

Pharmacy Times

In an interview with Pharmacy Times at the 2025 Oncology Pharmacists Connect (OPC) meeting, Scott Soefje, PharmD, MBA, BCOP, director of pharmacy at Mayo Clinic, focused on the evolving role of pharmacists in healthcare, highlighting their increasing presence in outpatient settings to enhance efficiency and patient care.

article thumbnail

Pharmacist-Led Interventions Show Promise in Improving COPD Outcomes

Drug Topics

1 “Eligible outcomes included changes in health-related quality of life, medication adherence, hospitalization rates, inhalation techniques, or disease-related knowledge." " Finally, pharmacist-led interventions were all conducted in community pharmacies, outpatient clinics, or hospital settings. Mayo Clinic Staff.

article thumbnail

Nemolizumab Shows Rapid, Sustained Efficacy in Atopic Dermatitis

Pharmacy Times

Mayo Clinic. RAD 2025: Long-term data on Nemluvio® (nemolizumab) demonstrate its favorable safety profile and sustained and increased improvements in itch and skin lesions in patients with atopic dermatitis up to two years. News release. June 6, 2025. Accessed June 16, 2025. Atopic Dermatitis. News release. May 15, 2024. Ferruggia K.

article thumbnail

Immunotherapy Takes the Lead in Advanced Cutaneous Malignancies

Pharmacy Times

Have you observed these immune-related toxicities in your practice, and if so, how are they being managed? All patients should have immunotherapy first. Pharmacy Times : As immunotherapies expand into the solid tumor space, clinicians are reporting cases of ICANS and CRS. It was approved last year.

article thumbnail

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

This act…allowed a pathway for manufacturers to create a ‘copy’ of a licensed patent product to make it cheaper and more discounted,” Soefje, director of pharmacy cancer care services and associate professor of pharmacy at Mayo Clinic in Rochester, Minnesota, said at the HOPA conference.

FDA 65